Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.

AIMS Several randomized trials with metabolic outcomes have reported that glucagon like peptide-1 receptor agonists (GLP-1 RA) could be associated with an increased risk of pancreatitis. The present meta-analysis aimed to examine this hypothesis. METHODS An extensive Medline, Embase, and Cochrane Database search for "exenatide", "liraglutide", "albiglutide", "taspoglutide", "dulaglutide", "lixisenatide", and "semaglutide" was performed up to March 31st, 2013. INCLUSION CRITERIA (i) randomized trials, (ii) duration ≥12 weeks; (iii) on type 2 diabetes; and (iv) comparison of GLP-1RA with placebo or active drugs. Mantel-Haenszel odds ratio with 95% confidence interval (MH-OR) was calculated for pancreatitis. RESULTS 80 eligible trials were identified. Of these, 39 had not disclosed their findings or did not report any information on pancreatitis. The remaining 41 trials enrolled 14,972 patients, with a total exposure of 14,333 patient × years (8353 and 5980 patient × years for GLP-1 receptor agonists and comparators, respectively). The overall risk of pancreatitis was not different between GLP-1RA and comparators (MH-OR: 1.01[0.37; 2.76]; p = 0.99). CONCLUSIONS The present meta-analysis does not suggest any increase in the risk of pancreatitis with the use of GLP-1RA. However, it should be recognized that the number of observed cases of incident pancreatitis is very small and the confidence intervals of risk estimates are wide.

• Publication year

  2014

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabres.2014.01.010PMID 24485345
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

  2013influential reference
• Incretin-based therapies and cardiovascular risk

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• GLP-1 receptor agonists: A clinical perspective on cardiovascular effects

  2012cited by this paper
• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  2011cited by this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

  2011cited by this paper
• Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

  2011cited by this paper
• Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

  2010cited by this paper
• Incretin-based therapies: review of current clinical trial data.

  2010cited by this paper
• Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

  2009cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper

• The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases.

  2026cites this paper
• Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems

  2026cites this paper
• Modulation of GLP-1 signalling as an innovative strategy counteracting the onset of heart failure: potential for natural compound supplementation.

  2025cites this paper
• GLP-1RA: New Hope in Obesity Therapy

  2025cites this paper
• Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients.

  2025cites this paper
• Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences

  2025cites this paper
• Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.

  2025cites this paper
• The Impact and Safety of GLP‐1 Agents and Breast Cancer

  2025cites this paper
• A Probable Case of Tirzepatide-Induced Acute Pancreatitis

  2025cites this paper
• Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI

  2025cites this paper
• Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases

  2025cites this paper
• Development of a non-enzymatic glucose sensor with nickel–cobalt-zinc composite prepared via hydrothermal-molten salt synthesis

  2025cites this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cites this paper
• Critical Analysis of the Efficacy and Limitations of GLP-1 Pharmaceuticals in Obesity Management: A Comprehensive Literature Review

  2024influential citation
• Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.

  2024cites this paper
• Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database

  2024cites this paper
• Electrosynthesis of tunable NiO/CuO-printed circuit board electrodes for glucose sensing

  2024cites this paper
• GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?

  2024cites this paper
• Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective

  2024cites this paper
• Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes

  2023cites this paper
• Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials

  2023cites this paper
• Electrochemical-Based Sensing Platforms for Detection of Glucose and H2O2 by Porous Metal–Organic Frameworks: A Review of Status and Prospects

  2023cites this paper
• The role of GLP-1 receptor agonists in managing type 2 diabetes

  2022cites this paper
• Sensitive Non-Enzymatic Glucose Electrochemical Sensor Based on Electrochemically Synthesized PANI/Bimetallic Oxide Composite

  2022cites this paper
• Employing an “aging paradox” to uncover effective measures for advancing productive longevity

  2022cites this paper
• Promoting non-enzymatic electrochemical sensing performance toward glucose by the integration of conducting polypyrrole with metal-organic framework

  2022cites this paper
• Combatting chronic metabolic disorders and delaying aging by improving glucose-insulin metabolism and fat accumulation in nondiabetics

  2022cites this paper
• PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides

  2022influential citation
• The role of GLP-1 receptor agonists in managing type 2 diabetes.

  2022cites this paper
• Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes

  2020cites this paper
• The SEEN comprehensive clinical survey of adult obesity: Executive summary.

  2020cites this paper
• Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study

  2020cites this paper
• Prévention et prise en charge du diabète de type 2 chez les patients souffrant de schizophrénie traités par antipsychotiques de seconde génération

  2020cites this paper
• GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials

  2020cites this paper
• GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.

  2020cites this paper
• Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials

  2019cites this paper
• Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

  2019cites this paper
• High-performance non-enzymatic glucose sensor by hierarchical flower-like nickel(II)-based MOF/carbon nanotubes composite.

  2019cites this paper
• Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis

  2019cites this paper
• Nonenzymatic Glucose Sensing and Magnetic Property Based On the Composite Formed by Encapsulating Ag Nanoparticles in Cluster-Based Co-MOF.

  2019cites this paper
• An evaluation of liraglutide including its efficacy and safety for the treatment of obesity

  2019cites this paper
• Personalized Management of Type 2 Diabetes

  2019cites this paper
• It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth

  2019cites this paper
• Preexisting Diabetes Elevates Risk of Local and Systemic Complications in Acute Pancreatitis

  2018cites this paper
• Colitis reducing effects of Lactobacillus plantarum YS-4 in dextran sulfate sodium-induced C57BL/6J mice

  2018cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2016

  2018cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2016

  2018cites this paper
• Exendin-4 dose not evoke pancreatitis or pancreatitis-associated histopathological and genetic changes in high-fat diet induced diabetic mice

  2018cites this paper
• Coriolus versicolor aqueous extract ameliorates insulin resistance with PI3K/Akt and p38 MAPK signaling pathways involved in diabetic skeletal muscle

  2018cites this paper
• Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2018cites this paper
• Gut-Derived Hormones , Secreted in Response to Salt Sensors , Modulate Renal Sodium Excretion

  2017cites this paper
• Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.

  2017cites this paper
• Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials

  2017cites this paper
• NEW ANTIDIABETIC DRUGS: WhaT pLace shOuLD TheY haVe iN TherapeuTics?

  2017cites this paper
• Non‐Insulin Parenteral Therapies

  2016cites this paper
• The Validity of the Assessment Criteria and Data Extraction in Meta-Analysis Articles

  2016cites this paper
• Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program

  2016cites this paper
• [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].

  2016cites this paper
• An overview of new GLP-1 receptor agonists for type 2 diabetes

  2016cites this paper
• A Plethora of GLP-1 Agonists: Decisions About What to Use and When

  2016cites this paper
• [Drugs affecting the incretin system and renal glucose transport: do they meet the expectations of modern therapy of type 2 diabetes?].

  2016cites this paper
• Investigational glucagon-like peptide-1 agonists for the treatment of obesity

  2016cites this paper
• Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials

  2016cites this paper
• Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review

  2016cites this paper
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

  2016cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes:A Clinical Update of Safety and Efficacy

  2016cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

  2016cites this paper
• Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

  2016cites this paper
• Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.

  2015cites this paper
• Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

  2015cites this paper
• Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes

  2015cites this paper
• Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

  2015cites this paper
• Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies

  2015cites this paper
• Insulin, Other Hypoglycemic Drugs, and Glucagon

  2015cites this paper
• Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

  2015cites this paper
• Liraglutide for Type 2 diabetes and obesity: a 2015 update

  2015cites this paper
• Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer

  2015cites this paper
• Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.

  2015cites this paper
• Cardiometabolic Effects of a New Class of Antidiabetic Agents.

  2015cites this paper
• Potential side effects to GLP-1 agonists: understanding their safety and tolerability

  2015cites this paper
• Drug-induced acute pancreatitis

  2015cites this paper
• GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond

  2015cites this paper
• Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

  2015cites this paper
• User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists

  2015cites this paper
• The Influence of Polypharmacy on Nutrition

  2015cites this paper
• Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

  2014cites this paper
• Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making

  2014cites this paper
• Risk of pancreatitis in patients treated with incretin-based therapies

  2014cites this paper
• Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

  2014cites this paper
• Dulaglutide for the treatment of type 2 diabetes.

  2014cites this paper
• Antihyperglycaemic therapies and cancer risk

  2014cites this paper
• Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!

  2014cites this paper
• Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

  2014cites this paper
• Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.

  2014cites this paper
• Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes

  2014cites this paper
• LE MÉDICAMENT DU MOIS Bydureon ® : premier agoniste des récepteurs du GLP-1 en une injection hebdomadaire (exénatide à libération prolongée)

  2014cites this paper
• Adverse Effects of GLP-1 Receptor Agonists.

  2014cites this paper
• Therapies for inter-relating diabetes and obesity – GLP-1 and obesity

  2014cites this paper
• Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus

  2014cites this paper
• World Journal of Diabetes

  year unknowncites this paper